Jump to content

Sio Gene Therapies

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 50.75.206.4 (talk) at 13:09, 10 April 2017. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Axovant Sciences
NYSE: AXON
IndustryBiopharmaceutical
FounderVivek Ramaswamy
Key people
Dr. David Hung (CEO)
Websiteaxovant.com

Axovant Sciences, Ltd. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.[1] The Hamilton, Bermuda-based company has offices in Basel, Switzerland and New York City and is traded on the New York Stock Exchange.[2][3]

History

Axovant was founded by Vivek Ramaswamy. Dr. David Hung serves as the Chief Executive Officer .[4] Ramaswamy founded Roivant Sciences in May 2014, and created Axovant as a subsidiary of Roivant in October of that year.[5][6] Axovant's initial public offering in 2015 was the highest grossing IPO in the biotechnology industry to date.

Pipeline

The company's most advanced drug candidate is intepirdine, a potential add-on treatment to donepezil for patients with Alzheimer's disease and patients with dementia with Lewy bodies.[7][6][8] Axovant acquired this molecule (previously known as SB-742457) from GlaxoSmithKline in December 2014. [5][9] Intepirdine is currently being evaluated in a Phase 3 clinical study for patients with mild to moderate Alzheimer's disease.[10] It is also being tested in an ongoing Phase 2b study for patients with dementia with Lewy Bodies, as well as a Phase 2 study evaluating its effect on gait and balance for patients with dementia.[11][12]

Axovant is simultaneously developing a second compound, nelotanserin. Axovant acquired global rights to nelotanserin from Roivant Sciences, which had previously bought those rights from Arena Pharmaceuticals.[1][8] Axovant has two ongoing Phase 2 clinical trials examining the use of nelotanserin for the treatment of visual hallucinations in subjects with Lewy Body Dementia as well as rapid eye movement sleep behavior disorder in patients with dementia with Lewy bodies.[8][13][14]

Axovant is investigating combinations of cholinesterase inhibitors with glycopyrrolate. Cholinesterase inhibitors have known gastrointestinal side-effects. Glycopyrrolate, as a muscarinic receptor antagonist, may reduce the side effects of cholinesterase inhibitors. The company is developing RVT-103, a combination of glycopyrrolate and donepezil, and RVT-104, a combination of glycopyrrolate and high-dose rivastigmine. [15]

References

  1. ^ a b "10-Q". www.sec.gov. Retrieved 2016-01-07.
  2. ^ "Axovant Investors".
  3. ^ "AXON Stock News - Axovant Sciences Stock". Seeking Alpha. Retrieved 12 Jun 2015.
  4. ^ "Axovant Leadership Team".
  5. ^ a b Pollack, Andrew (11 Jun 2015). "Shares of Axovant, Alzheimer's Drug Developer, Surge on Trading Debut". New York Times.
  6. ^ a b Karerat, Raif (12 Jun 2015). "Axovant Sciences founded by Indian American Vivek Ramaswamy has biggest US biotech IPO". The American Bazaar. Germantown, Maryland: Global Media Holding.
  7. ^ Staff (12 Jun 2015). "Axovant doubles in value after $315M IPO". Pharmaceutical Processing. Associated Press.
  8. ^ a b c Crow, David (2015-11-02). "Axovant prepares to start pair of dementia drugs trials". Financial Times. ISSN 0307-1766. Retrieved 2016-01-07.
  9. ^ House, Douglas W. (5 Jun 2015). "Axovant Sciences on deck for IPO". Seeking Alpha.
  10. ^ "Study Evaluating RVT-101 in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil Treatment: MINDSET Study - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2016-01-07.
  11. ^ "Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study". clinicaltrials.gov. Retrieved 11 November 2016.
  12. ^ "Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia". clinicaltrials.gov. Retrieved 11 November 2016.
  13. ^ "Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body Dementia - No Study Results Posted - ClinicalTrials.gov". www.clinicaltrials.gov. Retrieved 2016-01-07.
  14. ^ Al-Shamma, Hussien A.; Anderson, Christen; Chuang, Emil; Luthringer, Remy; Grottick, Andrew J.; Hauser, Erin; Morgan, Michael; Shanahan, William; Teegarden, Bradley R. (2010-01-01). "Nelotanserin, a novel selective human 5-hydroxytryptamine2A inverse agonist for the treatment of insomnia". The Journal of Pharmacology and Experimental Therapeutics. 332 (1): 281–290. doi:10.1124/jpet.109.160994. ISSN 1521-0103. PMID 19841476.
  15. ^ "Avoxant Pipeline".

Further reading

Retrieved from "https://en.wikipedia.org/w/index.php?title=Sio_Gene_Therapies&oldid=774750223"